Latest News and Events

Drug Developed at U of MN Increases Survival in Dogs with Cancer

The University of Minnesota recently published significant results involving a breakthrough trial which demonstrated improved survival rates for dogs diagnosed with hemangiosarcoma (HSA). (See the article in Molecular Cancer Therapeutics).

Emma - Sarcoma survivor dog

Canine HSA is a vascular cancer (involving blood vessels) and is very similar to angiosarcoma in humans. Both cancers are aggressive and spread before diagnosis, typically with devastating results.

The study used the UMN-developed drug eBAT which simultaneously targets the tumor and its vascular system. Results showed a substantial six-month survival rate for the 23 dogs in the study, with five dogs surviving beyond 450 days. The study also determined a dose of eBAT that allowed effective treatment with substantially fewer side effects.

The researchers believe the study’s positive results, along with the similarities between HSA and angiosarcoma in humans, make a strong case for potential clinical trials for human cancer patients.

Rein in Sarcoma was one of many funding sources for this research. See the announcement of 2017 RIS sarcoma research grants to the University of Minnesota.

For more details on the research study see the University of Minnesota press release. You can also view a KARE11 logo segment featuring this story.

U of M Biology of Osteosarcoma (BOOST) Registry and Biobank

University of Minnesota Health logo

Opportunity for Osteosarcoma patients and families

The University of Minnesota Masonic Cancer Center recently established the Biology of Osteosarcoma (BOOST) Registry and Biobank which offers a single location where every patient with osteosarcoma and their relatives can participate in research. The hope is that by gathering information on a very large number of osteosarcoma patients and their families from all over the world, researchers can gain a better understanding of osteosarcoma incidence and survival which may lead to the ability to predict who is susceptible, detect tumors when they are small and eventually a cure.

The BOOST registry and ongoing University of Minnesota osteosarcoma research is made possible in part through the Zach Sobiech Osteosarcoma Fund of the Children's Cancer Research Fund, as well as the Rein in Sarcoma Foundation.

Read More

Introducing New Board Members

The following new members were elected to the RIS Board of Directors at the January 29 Annual Meeting:

New Board Members- 2017

Ted Erickson, Tom McCarthy, Chelsey Olafson, Denis Clohisy, MD

Chelsey Olafson, is a sarcoma survivor . She helms the RIS Facebook Page and serves on the Patient and Family Support and PR/Marketing Committees. Chelsey will also be chairing the 2017 Party in the Park.

Thomas McCarthy, is a CPA and MBA and a Accounting Policy and Research Consultant at Securian Financial Group. He received his MBA at the Carlson School of Management of the University of Minnesota. He will serve as the organization’s new treasurer.

Dr. Denis Clohisy, is a Professor and Chairman of the Department of Orthopaedic Surgery at the University of Minnesota and a member of the University of Minnesota Cancer Center. Dr. Clohisy has been a longtime supporter of RIS.

Deb Cossette, Deb’s husband is a sarcoma survivor. Deb serves on the PR Committee as the Website Master, and she has become a Salesforce expert. Recently retired from 3M, Deb is incredibly organized and committed to RIS’ vision and goals. She will serve as Rein in Sarcoma’s Vice-President.

Ted Erickson, is Vice Chair at Holiday Companies and will serve on the RIS Development Committee. He currently is also a board member at PACER and the Minnesota Land Trust.

Renewing their leadership commitment to RIS for a second three-year term are Larry Seymour, MD and sarcoma survivor, Allan Swartz.

Thank you to all the Board members who serve RIS!

Recent and Upcoming Events